Brocade: Analysts' Upgrades, Downgrades

NEW YORK (TheStreet) -- CHANGE IN RATINGS

Aeropostale(ARO) upgraded at Goldman from Sell to Neutral. $34 price target. Valuation call, as the stock is already pricing in decelerating margins and limited store growth potential.

Buckle (BKE) rated new Sell at Goldman. $27 price target. Company faces near-term earnings risk and the company has few long-term opportunities for square-footage growth.

Burlington Northern Santa Fe (BNI) downgraded at Barclays to Underweight from Equal Weight. Price target lifted to $100 from $90. 2009 and 2010 EPS estimates maintained at $5.06 and $6.35, respectively.

Brocade (BRCD) downgraded at Piper from Overweight to Neutral. $9 price target. OEM strategy is not working as planned. Estimates also lowered, as channel checks reflect some weakness.

Brocade (BRCD) downgraded at ThinkEquity from Buy to Hold. Company will see more competition, following the HPQ/COMS deal.

Coach (COH) rated new Hold at Keybanc. Valuation call, as the stock is already pricing in long-term growth potential.

CSX (CSX) upgraded at Barclays to Equal Weight from Underweight. Improving volume outlook in 2010. Price target surged to $52 from $46. 2009 and 2010 EPS estimate maintained at $2.85 and $3.40, respectively.

Lear (LEA) initiated at Barclays with an Overweight rating and $82 price target. 2009 and 2010 EPS estimates set at -$3.24 and $2.85, respectively.

Merck (MRK) rated new Equal-weight at Morgan Stanley. $34 price target. Expect no earnings growth through 2013, as the expectations in the cholesterol franchise are likely too high.